Gli1 confers profound phenotypic changes upon lncap prostate cancer cells that include the acquisition of a hormone independent state

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Nadendla, Sandeep K ^a,b   Hazan, Allon ^a   Ward, Matt ^a   Harper, Lisa J ^a   Moutasim, Karwan ^c   Bianchi, Lucia S ^a   Naase, Mahmoud ^b   Ghali, Lucy ^b   Thomas, Gareth J ^c   Prowse, David M ^a   Philpott, Michael P ^a   Neill, Graham W ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MIDDLESEX UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA1 INTEGRIN; BICALUTAMIDE; BMI1 PROTEIN; HERMES ANTIGEN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; ANDROGEN; GLI1 PROTEIN, HUMAN; LUCIFERASE; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CELL INVASION; CELL STRAIN LNCAP; CELL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL ADHESION; CELL LINE; CELL PROLIFERATION; CELL SHAPE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANDROGENS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 79957502928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020271     Document Type: Article

References (88)

1. Mimeault M, Batra SK, (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22.
2. Wang ZA, Shen MM, (2011) Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 30: 1261-1271.
3. Liu AY, True LD, LaTray L, Ellis WJ, Vessella RL, et al. (1999) Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 40: 192-199.
4. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA, (2001) Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 195: 563-570.
5. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL, (2008) CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98: 756-765.
6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
7. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG, (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67: 6796-6805.
8. Wei C, Guomin W, Yujun L, Ruizhe Q, (2007) Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 6: 763-768.
9. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, et al. (2009) In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 69: 1683-1693.
10. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, et al. (2010) Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 70: 491-501.
11. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, et al. (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68: 9703-9711.
12. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, et al. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
13. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, et al. (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 107: 2610-2615.
14. Kasper M, Regl G, Frischauf AM, Aberger F, (2006) GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 42: 437-445.
15. Stecca B, Ruiz IAA, (2010) Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol 2: 84-95.
16. Teglund S, Toftgard R, (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805: 181-208.
17. Datta S, Datta MW, (2006) Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci 63: 435-448.
18. Shaw A, Bushman W, (2007) Hedgehog signaling in the prostate. J Urol 177: 832-838.
19. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, et al. (2004) Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 101: 12561-12566.
20. Chen BY, Liu JY, Chang HH, Chang CP, Lo WY, et al. (2007) Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis. Biochem Biophys Res Commun 357: 1084-1089.
21. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, et al. (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431: 707-712.
22. Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, et al. (2004) Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145: 3961-3970.
23. Narita S, So A, Ettinger S, Hayashi N, Muramaki M, et al. (2008) GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res 14: 5769-5777.
24. Shaw G, Price AM, Ktori E, Bisson I, Purkis PE, et al. (2008) Hedgehog signalling in androgen independent prostate cancer. Eur Urol 54: 1333-1343.
25. Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, et al. (2008) Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol 216: 460-470.
26. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, et al. (2009) Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 8: 149-157.
27. Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, et al. (2010) Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer 9: 89.
28. Chen G, Goto Y, Sakamoto R, Tanaka K, Matsubara E, et al. (2011) GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor. Biochem Biophys Res Commun 404: 809-815.
29. Creighton CJ, (2007) A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics 8: 199.
30. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
31. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
32. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL, (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95: 15587-15591.
33. Singh A, Settleman J, (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene.
34. Barr S, Thomson S, Buck E, Russo S, Petti F, et al. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 25: 685-693.
35. Thiyagarajan S, Bhatia N, Reagan-Shaw S, Cozma D, Thomas-Tikhonenko A, et al. (2007) Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res 67: 10642-10646.
36. Lauth M, Bergstrom A, Shimokawa T, Toftgard R, (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 104: 8455-8460.
37. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, et al. (2006) Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem 281: 19320-19326.
38. Kise Y, Takenaka K, Tezuka T, Yamamoto T, Miki H, (2006) Fused kinase is stabilized by Cdc37/Hsp90 and enhances Gli protein levels. Biochem Biophys Res Commun 351: 78-84.
39. Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, et al. (2006) Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 26: 6283-6298.
40. Riobo NA, Haines GM, Emerson CP Jr, (2006) Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer Res 66: 839-845.
41. Riobo NA, Lu K, Ai X, Haines GM, Emerson CP Jr, (2006) Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A 103: 4505-4510.
42. Nadiminty N, Dutt S, Tepper C, Gao AC, (2010) Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate 70: 276-287.
43. Dean M, (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9.
44. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS, (2007) Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26: 5674-5679.
45. Zhang Y, Laterra J, Pomper MG, (2009) Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 11: 96-101.
46. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, et al. (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395-1399.
47. Yan L, Borregaard N, Kjeldsen L, Moses MA, (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276: 37258-37265.
48. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, et al. (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A 106: 3913-3918.
49. Zhao J, Chen G, Cao D, Li Y, Diao F, et al. (2009) Expression of Gli1 correlates with the transition of breast cancer cells to estrogen-independent growth. Breast Cancer Res Treat.
50. Fiaschi M, Rozell B, Bergstrom A, Toftgard R, (2009) Development of mammary tumors by conditional expression of GLI1. Cancer Res 69: 4810-4817.
51. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984.
52. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, et al. (1998) Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 79: 565-572.
53. Tokes AM, Kulka J, Paku S, Szik A, Paska C, et al. (2005) Claudin-1,-3 and-4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7: R296-305.
54. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, et al. (2007) Loss of claudins-1 and-7 and expression of claudins-3 and-4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 38: 564-569.
55. Szasz AM, Nyirady P, Majoros A, Szendroi A, Szucs M, et al. (2010) beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 105: 716-722.
56. Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, et al. (2009) Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 454: 647-656.
57. Myal Y, Leygue E, Blanchard AA, (2010) Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers. J Biomed Biotechnol 2010: 956897.
58. Krajewska M, Olson AH, Mercola D, Reed JC, Krajewski S, (2007) Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate. Prostate 67: 907-910.
59. Vare P, Loikkanen I, Hirvikoski P, Vaarala MH, Soini Y, (2008) Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncol Rep 19: 25-31.
60. Prasad PD, Stanton JA, Assinder SJ, (2009) Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell Tissue Res 339: 337-347.
61. Lee EK, Han GY, Park HW, Song YJ, Kim CW, (2010) Transgelin Promotes Migration and Invasion of Cancer Stem Cells. J Proteome Res.
62. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. (2009) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis.
63. Liu AY, Nelson PS, van den Engh G, Hood L, (2002) Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 50: 92-103.
64. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, et al. (1992) Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52: 6182-6187.
65. Dennler S, Andre J, Alexaki I, Li A, Magnaldo T, et al. (2007) Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 67: 6981-6986.
66. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z, (2005) Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11: 4512-4520.
67. Lu S, Lee J, Revelo M, Wang X, Dong Z, (2007) Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 13: 5692-5702.
68. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, et al. (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58: 5310-5314.
69. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, et al. (2000) Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60: 3623-3630.
70. Ozen M, Creighton CJ, Ozdemir M, Ittmann M, (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793.
71. Sun R, Fu X, Li Y, Xie Y, Mao Y, (2009) Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 10: 93.
72. Wang G, Wang Y, Feng W, Wang X, Yang JY, et al. (2008) Transcription factor and microRNA regulation in androgen-dependent and-independent prostate cancer cells. BMC Genomics 9 (Suppl 2): S22.
73. Sun T, Wang Q, Balk S, Brown M, Lee GS, et al. (2009) The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 69: 3356-3363.
74. Tessel MA, Krett NL, Rosen ST, (2010) Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol 22: 592-597.
75. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC, (2010) miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer.
76. Wang XQ, Rothnagel JA, (2001) Post-transcriptional regulation of the gli1 oncogene by the expression of alternative 5′ untranslated regions. J Biol Chem 276: 1311-1316.
77. Shimokawa T, Tostar U, Lauth M, Palaniswamy R, Kasper M, et al. (2008) Novel human glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanisms in the terminal transduction of the hedgehog signal. J Biol Chem 283: 14345-14354.
78. Tanimura A, Dan S, Yoshida M, (1998) Cloning of novel isoforms of the human Gli2 oncogene and their activities to enhance tax-dependent transcription of the human T-cell leukemia virus type 1 genome. J Virol 72: 3958-3964.
79. Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, et al. (2005) A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet 14: 2181-2188.
80. Speek M, Njunkova O, Pata I, Valdre E, Kogerman P, (2006) A potential role of alternative splicing in the regulation of the transcriptional activity of human GLI2 in gonadal tissues. BMC Mol Biol 7: 13.
81. Lang SH, Stower M, Maitland NJ, (2000) In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates. Br J Cancer 82: 990-997.
82. Neill GW, Harrison WJ, Ikram MS, Williams TD, Bianchi LS, et al. (2008) GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes. Carcinogenesis 29: 738-746.
83. Neill GW, Ghali LR, Green JL, Ikram MS, Philpott MP, et al. (2003) Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma. Cancer Res 63: 4692-4697.
84. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
85. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
86. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
87. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
88. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4 microarray software suite. Methods Enzymol 411: 134-193.